Unternehmensportrait
Viking Therapeutics, Inc. is a biopharmaceutical company developing therapies for metabolic and endocrine disorders. Its lead candidate, VK2809, is in Phase IIb trials for non-alcoholic steatohepatitis. The company also focuses on treatments for diabetes and X-linked adrenoleukodystrophy.
Vorstand & Aufsichtsrat
| Vorstandsvorsitzender |
| Brian Lian |
| Vorstand |
| Greg Zante, Marianne Mancini, Geoffrey Barker, Michael Morneau |
| Aufsichtsrat |
| Lawson Macartney, Matthew W. Foehr, Kathy Rouan, Charles A. Rowland Jr., Matthew Singleton |
Unternehmensinformationen
| Name: |
Viking Therapeutics Inc. |
| Adresse: |
9920 Pacific Heights Blvd, Suite 350,San Diego, CA 92121 |
| Telefon: |
+1-858-704-4660 |
| Fax: |
- |
| E-Mail: |
-
|
| Internet: |
https://vikingtherapeutics.com/ |
| Industrie: |
Biotechnologie |
| Sektor: |
Biotechnologie |
| Sub-Sektor: |
Biotechnologie |
| Ende des Finanzjahres: |
31.12 |
| Streubesitz: |
92,05% |
| IPO Datum: |
- |
